Study: NCT03288545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin (EV)
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV infusion on days 1 and 8 every 21 days